IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER

被引：0
|
作者：
Vaidya, T. R. [1 ]
Ait-Oudhia, S. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Orlando, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-003
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [31] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [32] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [33] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [34] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [35] IGF2 activation of HER2 receptor in HER2 positive breast cancer cell lines
    Helu, Xousaen M.
    De Leon, Daisy D.
    CANCER RESEARCH, 2012, 72
  • [36] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [37] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [38] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [39] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [40] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345